Triazole derivative as an HSP 90 inhibitor

Details for Australian Patent Application No. 2007344512 (hide)

Owner Merck Patent GmbH

Inventors Sirrenberg, Christian; Eggenweiler, Hans-Michael; Buchstaller, Hans-Peter; Wolf, Michael

Agent Davies Collison Cave

Pub. Number AU-B-2007344512

PCT Pub. Number WO2008/086857

Priority 10 2007 002 715 .1 18.01.07 DE

Filing date 11 December 2007

Wipo publication date 24 July 2008

Acceptance publication date 1 November 2012

International Classifications

C07D 249/12 Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms

A61K 31/4196 - 1,2,4-Triazoles

A61P 35/00 Antineoplastic agents

C07F 9/09 Compounds containing elements of the 5th Group of the Periodic System

C07H 15/26 Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals

Event Publications

10 September 2009 PCT application entered the National Phase

  PCT publication WO2008/086857 Priority application(s): WO2008/086857

1 November 2012 Application Accepted

  Published as AU-B-2007344512

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007344522-Cable organization device

2007344509-5-([1,3,4] oxadiazol-2-yl)-1H-indazol and 5-([1,3,4] thiadiazol2-yl)-1H-indazol derivatives as SGK inhibitors for the treatment of diabetes